5 Things You Should Know Before the Stock Market Opens

NEW YORK ( TheStreet) -- U.S. stock futures were pointing to a slightly higher open for Wall Street Monday after a sharp rally on Friday closed out a month that saw the major indices post gains.

European stocks were rising while Asian shares ended mixed on Monday. Japan's Nikkei 225 index fell less than 0.1% to 9,003.48.

The Dow Jones Industrial Average soared nearly 278 points, or 2.2%, to close at 12,880 on Friday, rising rose 1.9% for the week and finishing June with a gain of nearly 4%.

The S&P 500 surged 33 points, or 2.5%, to finish Friday at 1362. The index rose 4% in June.

The Nasdaq gained nearly 86 points, or 3%, to settle Friday at 2935; the index added 3.8% in June.

Stocks got a boost last week from an agreement from European leaders to stabilize the region's banks.


The economic calendar in the U.S. Monday includes the Institute for Supply Management's June manufacturing index at 10 a.m. EDT; economists surveyed by Reuters expect a reading of 52.0 versus 53.5 in May.

Construction spending for May also is scheduled for 10 a.m.


Bristol-Myers Squibb ( BMY) is purchasing diabetes drugmaker Amylin Pharmaceuticals ( AMLN) in a deal valued at about $7 billion.

Bristol-Myers will pay $31 a share in cash for San Diego-based Amylin. The deal includes Amylin's net debt and a payment obligation to Eli Lilly bringing the total value of the transaction to about $7 billion, the companies said.

The purchase price offers a 9.9% premium of to Amylin's closing share price Friday of $28.20.


Germany's Linde agreed to buy Lincare Holdings ( LNCR) for about $3.8 billion.

Under the deal, Linde will pay $41.50 a share for Lincare, a leader in the U.S. home respiratory market.

Lincare shares closed Friday at $34.02.


The interest rate rigging scandal has claimed its first victim. Barclays PLC ( BCS)Chairman Marcus Agius departs following the bank's $453 million settlement of an investigation into alleged interest rate manipulation.

Regulators in the U.S. and the U.K. alleged that Barclays had submitted false data for setting the London interbank offered rate, or Libor, between 2005 and 2009. Agius has been chairman at Barclays since the beginning of 2007.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact